Tesamorelin is essentially a growth hormone-releasing factor (GRF) analog, composed of 44 amino acids with a hexanoyl side chain at the N-terminus. Instead of entering cells and triggering any fancy molecular switches, it directly targets the pituitary gland, prompting it to secrete more endogenous growth hormone (GH). GH then downstream stimulates IGF-1, ultimately promoting lipolysis and reducing visceral fat.
When the FDA approved it in 2010, HIV-related lipodystrophy was a significant challenge-highly active antiretroviral therapy (HAART) saved many lives, but also led to trunk fat accumulation and limb fat atrophy, resulting in a bizarre "buffalo hump" and "bulging belly." Tesamorelin addresses this issue.
Core Advantages and Functions
1. It is the FDA-approved "legitimate solution" for HIV-related lipodystrophy. While many products on the market claim to reduce visceral fat, Tesamorelin is one of the few with Phase III clinical trial support. In the pivotal LIPO-010 and CTR-1011 trials, it reduced visceral adipose tissue (VAT) by more than 8%, reaching the FDA's clinically significant threshold. For HIV patients suffering from lipodystrophy to the point of being afraid to even look in the mirror, this number represents a real restoration of dignity.
2. Instead of directly supplementing with exogenous GH, it allows the body to produce its own.
This is fundamentally different from directly injecting human growth hormone (HGH). Exogenous GH dosage is difficult to control, and there are numerous side effects; Tesamorelin takes the approach of "awakening the pituitary gland," which is theoretically more in line with physiological rhythms. Of course, this is only theoretical-in reality, IGF-1 will still rise, and the associated risks will remain.
3. Some improvement in lipid profile.
The trials observed a decreasing trend in total cholesterol and LDL, although the magnitude wasn't spectacular. For HIV patients, metabolic syndrome itself is a ticking time bomb, and any positive improvement is worth paying attention to.
4. Relatively Fast Onset of Action
Changes are generally noticeable within 1-2 weeks, with a significant reduction in abdominal fat within 4-6 weeks, and the effect stabilizes within 8-12 weeks. This timeline is acceptable for patients eager to improve their appearance and regain social confidence.
Storage Conditions (Divided into unreconstituted and reconstituted versions; do not confuse them):
Unreconstituted lyophilized powder (Egrifta SV old version): Refrigerate at 2–8℃, protected from light. Do not freeze. Store the diluent (sterile water) at room temperature.
Unreconstituted lyophilized powder (Egrifta WR 2024–2025 new formulation): Store at room temperature (20–25℃), protected from light. Refrigeration is not required; this is a more convenient feature compared to the old version.
After Reconstitution: SV old version must be prepared and administered immediately; any remaining product should be discarded. Do not refrigerate or freeze. WR new version, after reconstitution with antibacterial water, can be stored at room temperature (20–25℃) for a maximum of 7 days; discard on the 8th day.
Reconstitution Method: Add diluent along the wall and gently stir in a circular motion to dissolve. Do not shake. The solution should be clear, colorless, and free of particles. Discard any solution containing flocculent material.
Precautions:
Do not use prescription peptides/RUO indiscriminately. These are FDA prescription drugs, not the "belly-slimming peptides" found in the fitness world. Purchasing powder from overseas and injecting it into the abdomen daily is both compliant and unsafe.
Living tumors, pituitary axis damage (pituitary tumor/post-surgery/brain radiotherapy/Sheehan's syndrome), allergies to peptides or mannitol, pregnancy-all are strictly contraindicated. Avoid all of these. The GH/IGF-1 pathway will feed existing tumors.
During treatment, monitor IGF-1 (consider discontinuing if it continues to rise), fasting blood glucose/HbA1c (may induce or worsen impaired glucose tolerance, diabetes), edema/joint pain/carpal tunnel syndrome (the fluid retention aspect).
Common adverse reactions: redness, itching, and pain at the injection site; muscle pain and joint pain; peripheral edema; occasional allergic rashes; mortality rate is controversial in high GH state after acute and severe illness/major surgery; avoid administration during critical periods.
Administer subcutaneous injections in the abdomen on rotation, avoiding the navel, scars, and bruises; use personal needles, especially avoid sharing with HIV-positive individuals to prevent cross-infection.
The same applies to lyophilized powder used in research: dry at -20℃, protect from light, aliquot, and reconstitute according to brand stability (most follow the logic of clinical drugs: prepare and administer immediately or store briefly at 2–8℃, avoid repeated freeze-thaw cycles). Don't be fooled by claims that "peptide powder can be stored in the refrigerator."
Hot Tags: tesamorelin 2mg/vial, a peptide used for scientific research in china, China tesamorelin 2mg/vial, a peptide used for scientific research in china manufacturers, suppliers, factory
